Market Overview

AbbVie's Potential Is 'Underappreciated,' Says Morgan Stanley Analyst

AbbVie's Potential Is 'Underappreciated,' Says Morgan Stanley Analyst

Despite the pandemic risk, one analyst at Morgan Stanley remains bullish on AbbVie Inc (NYSE: ABBV).

The AbbVie Analyst

David Risinger maintained an Overweight on AbbVie with a $95 price target. 

The AbbVie Thesis

Risks to U.S. sales stemming from unemployment and the Humira patent cliff are likely to be  pushbacks for AbbVie, Risinger said in a Wednesday note. (See his track record here.)

AbbVie's U.S. commercial exposure is at 42% of global sales compared to Eli Lilly And Co's (NYSE: LLY) 30%, the analyst said. Notwithstanding the pushback, he said he sees AbbVie stock's valuation and yield as attractive. 

Though Risinger said he is cognizant of the patent cliff faced by AbbVie's rheumatoid arthritis drug Humira, he chooses to focus beyond that issue. Below-consensus sales of Humira in the 2023-24 period will be offset by higher excluding-Humira sales, the analyst said. 

Risinger sees the gentlest cliff for AbbVie. He estimates that 45% of the company's 2023 estimate is at risk to generic or biosimilar competition by 2030, which he said is the smallest percentage of five large-caps that include Merck & Co., Inc. (NYSE: MRK), Pfizer Inc. (NYSE: PFE), Lilly and Bristol-Myers Squibb Co (NYSE: BMY).

Discussing a "wildcard" catalyst for the stock, Risinger said AbbVie is due to release Phase 2 results on ABBV-3373 soon, with the investigational asset being an antibody-drug conjugate consisting of an anti-TNF antibody and a steroid.

Given the low odds of success and that the company hasn't yet demonstrated human efficacy proof-of-concept, the analyst said that if Phase 2 data is surprisingly compelling, AbbVie shares could step higher. If it fails, ABBV shares may only trade off slightly, he said. 

"We view Humira erosion fears as overly discounted and Abbvie's prospects as underappreciated."

ABBV Price Action

At last check, AbbVie shares were trading down 1.4% at $89.19. 

Related Links:

5 Biopharmas Where BofA Would Put Its Money To Work

The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight

Latest Ratings for ABBV

Nov 2020BMO CapitalInitiates Coverage OnOutperform
Nov 2020BernsteinInitiates Coverage OnOutperform
Nov 2020SVB LeerinkMaintainsOutperform

View More Analyst Ratings for ABBV
View the Latest Analyst Ratings


Related Articles (ABBV)

View Comments and Join the Discussion!

Posted-In: David Risinger Morgan StanleyAnalyst Color Biotech News Price Target Reiteration Analyst Ratings Best of Benzinga

Latest Ratings

PLTHCanaccord GenuityMaintains6.0
VLDRCraig-HallumInitiates Coverage On23.0
MFACNorthland Capital MarketsInitiates Coverage On15.0
CEREJefferiesInitiates Coverage On18.0
GIIIUBSInitiates Coverage On22.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at